NK cells and their receptors in naive and rituximab-treated patients with anti-MAG polyneuropathy

被引:3
|
作者
Benedetti, Luana [1 ]
Facco, Monica [2 ]
Franciotta, Diego [3 ]
Dalla Torre, Chiara [4 ]
Campagnolo, Marta [4 ]
Lucchetta, Marta [4 ]
Boscaro, Elisa [2 ]
Ermani, Mario [4 ]
Del Sette, Massimo [1 ]
Berno, Tamara [2 ]
Candiotto, Laura [2 ]
Zambello, Renato [2 ]
Briani, Chiara [4 ]
机构
[1] Osp S Andrea, Dept Neurol, La Spezia, Italy
[2] Univ Padua, Dept Med DIMED, I-35100 Padua, Italy
[3] Natl Inst Neurol C Mondino, IRCCS, Lab Neuroimmunol, Pavia, Italy
[4] Univ Padua, Dept Neurosci, I-35100 Padua, Italy
关键词
Natural killer (NK) cells; CD94/NKG2A; Myelin associated glycoprotein; Anti-MAG antibodies; IgM; Monoclonal gammopathy; Rituximab; NATURAL-KILLER-CELLS; PERIPHERAL-BLOOD; MULTIPLE-SCLEROSIS; MONOCLONAL-ANTIBODY; T-CELLS; AUTOIMMUNE; NEUROPATHY; DISEASE;
D O I
10.1016/j.jns.2013.05.015
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Natural killer (NK) cells can bridge innate and acquired immunity, and play a role in autoimmunity. A few studies evaluated the distribution of NK cells and the expression of their receptors in chronic immune-mediated demyelinating polyneuropathies. We investigated NK cell distribution and NK cell receptor expression in 20 naive patients with anti-MAG polyneuropathy (MAG-PN). Methods: Using flow cytometry, we analysed NK cells and a series of NK cell receptors in the peripheral blood of patients with MAG-PN, and, as controls, in patients with chronic inflammatory demyelinating peripheral polyradiculoneuropathy (CIDP) and in healthy subjects. Six MAG-PN patients were also tested after rituximab treatment. Results: At baseline the percentage of NK cells did not differ among the groups. KIR2DL2 receptor expression in MAG-PN patients was higher, andCD94/NKG2A receptor expression in both MAG-PN and CIDP patients was lower than in healthy controls. These abnormalities did not correlate with any clinical or demographic variable. No modification was found after rituximab therapy. Conclusions: The data suggest that MAG-PN shows abnormalities in NK cell receptors that characterise other autoimmune diseases, and cannot help in differential diagnosis with CIDP. The impairment of the relevant CD94/NKG2A inhibitory pathway, which might play a central role in the development and perpetuation of MAG-PN, warrants further functional investigations. (C) 2013 Elsevier B.V. All rights reserved.
引用
收藏
页码:86 / 89
页数:4
相关论文
共 50 条
  • [21] Predictive factors of efficacy of rituximab in patients with anti-MAG neuropathy
    Gazzola, Sebastien
    Delmont, Emilien
    Franques, Jerome
    Boucraut, Jose
    Salort-Campana, Emmanuelle
    Verschueren, Annie
    Sagui, Emmanuel
    Hubert, Anne-Michele
    Pouget, Jean
    Attarian, Shahram
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2017, 377 : 144 - 148
  • [22] Efficacy of rituximab in Anti-MAG neuropathy.
    Singh, Jaswinder
    Malani, Ashok
    Festoff, Barry
    Kambhampati, Suman
    BLOOD, 2006, 108 (11) : 370B - 371B
  • [23] A double-blind, placebo-controlled study of Rituximab in patients with Anti-MAG antibody-demyelinating polyneuropathy (A-MAG-DP)
    Dalakas, Marinos C.
    Rakocevic, Goran
    Salajegheh, Kian
    Damhrosia, James
    Raju, Raghavan
    McElroy, Beverly
    ANNALS OF NEUROLOGY, 2006, 60 : S91 - S91
  • [24] Coexistence of anti-MAG demyelinating polyneuropathy and CREST syndrome
    Zouvelou, V.
    Andreadou, E.
    Kolovou, D.
    Davaki, P.
    Sfagos, C.
    Kilindireas, C.
    EUROPEAN JOURNAL OF NEUROLOGY, 2004, 11 : 145 - 145
  • [25] A double-blind, placebo-controlled study of rituximab in patients with anti-MAG antibody-demyelinating polyneuropathy (A-MAG-DP)
    Dalakas, Marinos C.
    Rakocevic, Goran
    Salajegheh, Mohammad K.
    Dambrosia, James
    Hahn, Angelika
    Raju, Raghavan
    McElroy, Beverly
    NEUROLOGY, 2007, 68 (12) : A214 - A214
  • [26] Polyneuropathy attributes: a comparison between patients with anti-MAG and anti-sulfatide antibodies
    S. Erb
    F. Ferracin
    P. Fuhr
    K.M. Rösler
    C.W. Hess
    T. Kuntzer
    J. Bogousslavsky
    R. Sztajzel
    A.J. Steck
    Journal of Neurology, 2000, 247 : 767 - 772
  • [27] The clinical response of rituximab in patients with Anti-MAG antibody-demyelinating polyneuropathy (A-MAG-DP) is associated with alteration of lymphocyte homing and induction of regulatory T cells
    Raju, Raghavan
    Shi, Wei
    Dalakas, Marinos
    ANNALS OF NEUROLOGY, 2006, 60 : S95 - S95
  • [28] Characteristics of Patients with Anti-MAG Associated Neuropathy who Respond to Rituximab
    Chaar, David
    Kakara, Mihir
    Sriwastava, Shitiz
    Moshirzadeh, Sasan
    Halon, Michal
    Lisak, Robert
    NEUROLOGY, 2020, 94 (15)
  • [29] Polyneuropathy attributes:: a comparison between patients with anti-MAG and anti-snlfatide antibodies
    Erb, S
    Ferracin, F
    Fuhr, P
    Rösler, KM
    Hess, CE
    Kuntzer, T
    Bogousslavsky, J
    Sztajzel, R
    Steck, AJ
    JOURNAL OF NEUROLOGY, 2000, 247 (10) : 767 - 772
  • [30] Anti-MAG associated cerebellar ataxia and response to rituximab
    Zis, Panagiotis
    Rao, Dasappaiah Ganesh
    Hoggard, Nigel
    Sarrigiannis, Ptolemaios Georgios
    Hadjivassiliou, Marios
    JOURNAL OF NEUROLOGY, 2018, 265 (01) : 115 - 118